We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-8.13%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$611M
AUM Growth
-$116M
Cap. Flow
+$26.6M
Cap. Flow %
4.34%
Top 10 Hldgs %
81.82%
Holding
34
New
8
Increased
16
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$25.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$18.8M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$16.4M
4
DVAX
Dynavax Technologies
DVAX
+$7.03M
5
COGT icon
Cogent Biosciences
COGT
+$7.03M

Top Sells

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$10.9M
2
TVTX icon
Travere Therapeutics
TVTX
+$7.02M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$1.53M
4
VERA icon
Vera Therapeutics
VERA
+$754K
5
VRDN icon
Viridian Therapeutics
VRDN
+$187K

Sector Composition

Rank Sector Weight
1 Healthcare 98.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTB
26
Connect Biopharma Holdings
CNTB
$135M
$434K 0.07%
535,005
– –
GOSS icon
27
Gossamer Bio
GOSS
$66.5M
$208K 0.03%
+250,000
New +$288K
TVTX icon
28
CALL
Travere Therapeutics
TVTX
$5.33B
$135K 0.02%
+15,100
New +$213K
NGNE icon
29
Neurogene
NGNE
$696M
$94.9K 0.02%
6,009
+11
+0.2% +$162
GYRE icon
30
Gyre Therapeutics
GYRE
$662M
$43.4K 0.01%
6,004
+12
+0.2% +$80
ARGX icon
31
PUT
argenx
ARGX
$57.4B
– –
-184,300
Closed -$71.8M
KYNB
32
CALL
Kyntra Bio
KYNB
$28.5M
– –
-23,460
Closed -$1.58M
PTCT icon
33
CALL
PTC Therapeutics
PTCT
$6.37B
– –
-28,500
Closed -$1.16M
RYTM icon
34
Rhythm Pharmaceuticals
RYTM
$7B
– –
-92,602
Closed -$1.53M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Kynam Capital Management held 34 positions worth $611M, down 16% from $727M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Kynam Capital Management deployed $26.6M of net new capital in Q3 2023, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was ACELYRIN: 1,200,000 shares worth $12.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Olema Pharmaceuticals, an estimated $10.9M trimmed.

  • Kynam Capital Management's largest Q3 2023 buy was ACELYRIN: 1,200,000 shares worth $12.2M.
  • Kynam Capital Management added most to Celldex Therapeutics in Q3 2023, an estimated $18.8M increase.
  • Kynam Capital Management's biggest Q3 2023 reduction was Olema Pharmaceuticals, cutting an estimated $10.9M.
  • Kynam Capital Management fully exited Rhythm Pharmaceuticals in Q3 2023, selling an estimated $1.53M.
  • Kynam Capital Management's ten largest holdings make up 82% of its $611M portfolio in Q3 2023.
  • Kynam Capital Management opened 8 new positions and closed 4 in Q3 2023.
  • Kynam Capital Management's portfolio value fell 16% quarter-over-quarter to $611M.

Based on Kynam Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.